Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Rachel O. Abelman et al.|Annals of Oncology|2023Cited by 77
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.Rachel O. Abelman, Laura M. Spring, Shannon McLaughlin et al.|Journal of Clinical Oncology|2025Cited by 11